YD Bio began trading on Nasdaq as YDES after merging with Breeze Holdings, fuelling retail trader buzz. The firm expects $11.5 million in fresh funding and is shifting from drug supply to developing cancer diagnostics and eye disease therapies. Its pipeline includes pancreatic cancer tests and exosome-based eye treatments, with retail sentiment 'extremely bullish'.